Versant Capital Management’s Rapport Therapeutics RAPP Stock Holding History
Bought
Maintained
Sold
Other funds holding RAPP
Versant Capital Management's RAPP Position: Q3 2026 in Review
Versant Capital Management held its Rapport Therapeutics (RAPP) position steady in Q3 2026 at 27 shares worth $907. The position accounts for ﹤0.01% of the portfolio, ranked #2719.
Versant Capital Management first reported a position in RAPP in Q1 2026 and has held it in 3 quarters since. The position peaked at $1.12K in Q2 2026. 169 funds tracked by Wall St. Rank hold RAPP as of Q3 2026.
- Versant Capital Management held 27 shares of Rapport Therapeutics worth $907 as of Q3 2026.
- Versant Capital Management left its Rapport Therapeutics share count unchanged in Q3 2026.
- Rapport Therapeutics made up ﹤0.01% of Versant Capital Management's portfolio in Q3 2026, its #2719 holding.
- Versant Capital Management first reported a position in Rapport Therapeutics in Q1 2026 and has held it in 3 quarters since.
- Versant Capital Management's Rapport Therapeutics position peaked at $1.12K in Q2 2026.
- 169 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q3 2026.
Based on Versant Capital Management's 13F filing for Q3 2026, filed 2 Oct 2026.